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Background
Discrepancies between results obtained in phenotypic
drug resistance tests and genotype or phenotype interpre-
tation algorithms often lead to the recognition of impor-
tant resistance associated mutations. The drug resistance
profile of K66N, a novel mutation in HIV-1 reverse tran-
scriptase (RT) was identified as a result of discrepant phe-
notype/genotype results.
Methods
A recombinant clinical isolate from a patient failing his
antiretroviral treatment harboring the K66N and D67G
(1) mutations in RT had reduced susceptibility for lamivu-
dine (3TC) and emtricitabine (FTC) in a phenotypic assay
(Antivirogram®), while the genotype interpretation algo-
rithms (Virco® TYPE-HIV-1, Stanford & ANRS) showed a
susceptible profile for 3TC and FTC. The mean fold-
change (FC) values in the phenotypic assay (Antiviro-
gram®) were 6.2 for 3TC and 22.1 for FTC (2 measure-
ments each). A HIV-1 HXB2 site-directed mutant (SDM)
harboring K66N in the RT was tested in the phenotypic
assay. The Virco database was searched for isolates harbor-
ing K66N.
Summary of results
The FC values of SDM K66N in the phenotypic assay were
5.3 and 4.9 for 3TC and FTC, respectively (mean of four
measurements each). Antivirogram® biological cut-offs for
3TC and FTC are 2.1 and 3.0, respectively. The K66N
mutation was found to be rare, occurring in 0.026% of
queried sequences (77/292.910); 44% of the K66N iso-
lates found in the database harbored the mutation as a
mixture with the wild-type amino acid, while approxi-
mately 52% of all isolates with K66N had a pure K66N
mutation.
Conclusion
The mutation K66N in HIV-1 RT is associated with
reduced phenotypic susceptibility to 3TC and FTC. Fur-
ther research is required to investigate the clinical impact
of this finding, how the mutation evolves and whether it
is selected during a specific therapy.
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